ARS Pharma rises on positive results from repeat dose study of nasal spray

ARS Pharmaceuticals

20/02/2024 18:22

** Shares of ARS Pharmaceuticals  SPRY.O  rise 6.07% to
$7.61
    ** Co announces results from a study comparing repeat doses
of its nasal spray for allergic reactions, neffy, to repeat
doses of epinephrine injection
    ** The study was requested by the FDA when the health 
regulator declined to approve neffy in September
    ** Repeat doses of neffy showed a pharmacokinetic profile
greater than or similar to the epinephrine injection, and a
pharmacodynamic profile greater than the injection
    ** Pharmacokinetics is the study of how the body interacts
with the drugs for the entire duration of exposure, whereas
pharmacodynamics examines the drug's effect on the body more
closelythan
    ** The data is clearly supportive of the efficacy of neffy
and should alleviate any remaining concerns of the FDA, says
brokerage William Blair; upgrades shares to outperform
    ** Co intends to submit the data from the repeat dose study
to the FDA early in Q2 2024, expects to launch of neffy in H2
2024
    ** Stock has fallen ~13% in the last 12 months

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))